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OBJECTIVE — We describe the long-term outcomes of 510 diabetic patients with critical
limbischemia(CLI)andanactivefootulcerorgangrene,seenattheUniversityHospitalofRome
Tor Vergata, a tertiary care clinic.
RESEARCH DESIGN AND METHODS — These patients were seen between Novem-
ber 2002 and November 2007 (mean follow-up 20  13 months [range 1–66 months]). The
Texas Wound Classiﬁcation was used to grade these wounds that were either class C (ischemia)
and D (ischemiainfection) and grade 2–3 (deep–very deep). This comprehensive treatment
protocol includes rapid and extensive initial debridement, aggressive use of peripheral percuta-
neous angioplasty, empirical intravenous antibiotic therapy, and strict follow-up.
RESULTS — The protocol was totally applied (with percutaneous angioplasty [PA]) in 456
(89.4%) patients and partially (without percutaneous angioplasty [PA]) in 54 (10.6%) pa-
tients. Outcomes for the whole group and PA and PA patients are, respectively: healing, n 
310 (60.8%), n  284 (62.3%), and n  26 (48.1%); major amputation, n  80 (15.7%), n 
67(14.7%),andn13(24.1%);death,n83(16.25%),n68(14.9%),andn15(27.8%);
and nonhealing, n  37 (7.25%), n  37 (8.1%), and n  0 (0%) (
2 0.0009). Predicting
variables at multivariate analysis were the following: for healing, ulcer dimension, infection, and
ischemic heart disease; and for major amputation, ulcer dimension, number of minor amputa-
tions, and age. Additional predicting variables for PA patients were the following: for healing,
transcutaneous oxygen tension [TcPO2]; and for major amputation, basal TcPO2, basal A1C,
TcPO2, and percutaneous angioplasty technical failure.
CONCLUSIONS — Early diagnosis of CLI, aggressive treatment of infection, and extensive
use of percutaneous angioplasty in ischemic affected ulcers offers improved outcome for many
previouslyat-risklimbs.Ulcersize5cm
2indicatesareducedchanceofhealingandincreasedrisk
of major amputation. It was thought that all ulcers warrant aggressive treatment including percuta-
neous angioplasty and that treatment should be considered even for small ischemic ulcers.
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eripheral vascular disease (PVD) is
responsible for the increased risk of
lower limb amputation observed in
diabetic patients (1). A multidisciplinary
approach to diabetic foot problems is
mandatory to reduce the frequency of
lower limb amputations (2), particularly
whenPVDiscomplicatedbythepresence
of infected foot ulcers (3). However, very
few reports reveal successful treatments
toreducethefrequencyoflowerlimbam-
putations (4).
Today a signiﬁcantly better out-
come is expected for these patients,
based on improved technical options in
peripheral revascularization, new op-
tions in antibiotic therapy, and aggres-
sive wound debridement and wound
care.Increasedidentiﬁcationofriskfac-
torsandcomorbiditieshasprovidedim-
proved prognostication for this difﬁcult
problem.
One of the most important advances
is the increased availability of distal arte-
rialrevascularizationbydistalbypasssur-
gery and by percutaneous angioplasty
(5,6). This technique is increasingly im-
portant because of it is less invasive than
open procedures and it can be used to
treat very distal arterial stenosis and/or
obstructions.Itcanberepeatedincasesof
technicalfailure.Inaddition,theriskpro-
ﬁle with this procedure is much less than
that with more extensive open proce-
dures. Techniques such as subintimal an-
gioplasty, initially used only for femoral
and popliteal occlusions, are now applied
to long crural artery occlusions (7). Out-
comes from percutaneous angioplasty are
similar to those for open procedure coun-
terparts, at least when severe limb isch-
emia is due to infrainguinal disease (8). It
is difﬁcult to precisely quantify the clini-
calimprovementsofferedbythisprotocol
because previous studies were performed
using various outcome measures of distal
revascularization. These ranged from direct
technical success of revascularization, mea-
surement of ﬁnal wound healing, patency
rates of treated vessels, and ultimately limb
salvage rates (9). Because of this heteroge-
neity, statistical comparisons among these
studies are not easily performed.
Of additional concern in the patient
population with this difﬁcult problem is
the clinical heterogeneity of foot wounds
studied previously and how this affects
ﬁnal treatment outcomes (10). A more
standardized approach to both the objec-
tiveclinicalfeaturesofthetreatedwounds
andoutcomemeasuresisneededtoverify
the efﬁcacy of therapeutic approaches
aimedtosalvagelimbsindiabeticpatients
withcriticallimbischemia(CLI).Accord-
ing to the TransAtlantic Inter-Society
Consensus (TASC) classiﬁcation, CLI is
deﬁned by the presence of ulceration,
gangrene, or pain at rest and ankle pres-
sure 50–70 mmHg or toe pressure
30–50 mmHg or transcutaneous oxy-
gen tension (TcPO2) 30–50 mmHg as
reference values (9).
In this study, the clinical outcomes of
a large cohort of diabetic patients with
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greneseenconsecutivelyattheUniversity
HospitalofRomeTorVergataaredescribed.
The outcome measures used were healing,
nonhealing,majoramputation,andmortal-
ity.Nonhealingwasdeﬁnedaspatientswith
persistent ulceration after at least 1 year of
follow-up who had functional use of the
lower extremities and no evidence of in-
creasing infection.
RESEARCH DESIGN AND
METHODS— All of the diabetic pa-
tients seen at the outpatient diabetic foot
clinic or at the ﬁrst-aid station because of
a CLI and a foot ulcer and/or gangrene
classiﬁed as stage C (ischemia) or stage D
(ischemiainfection) and grade 2–3
(deep–very deep) according to the Texas
Wound Classiﬁcation (TWC) (11) were
considered eligible for our limb salvage
protocol.
Management protocol
The management protocol use in this
study includes early revascularization of
the affected limb with percutaneous an-
gioplasty, early and aggressive surgical
debridement of the ulcer and/or gan-
grene, and initialization of empirical
broad-spectrum intravenous antibiotic
therapy with at least two different drugs.
Additional attention was directed to
maintaining patients’ electrolyte balance,
andpatientswerehydratedinpreparation
for contrast angiography. Patients’ medi-
cal status was also optimized, including
intravenous insulin therapy and attention
to comorbidities including, in particular,
cardiovascular disease. A standard electro-
cardiogram and echocardiogram were per-
formed. A heart scan was also performed in
selected patients. Standard Doppler ultra-
soundofthecarotidarterieswasperformed
in all patients. The procedures used were
vascular assessment, revascularization pro-
cedure, aggressive surgical debridement,
and infection treatment.
Vascular assessment. Magnetic reso-
nanceangiographyofthelowerlimbswas
performed to detect arterial stenosis
and/or obstructions and to determine
when interventional treatment was war-
ranted, the “road map” of treatment. The
team policy was to treat all patients with
CLI whenever possible with percutane-
ous angioplasty, reserving distal bypass
for patients treated unsuccessfully with
percutaneous angioplasty. TcPO2 (12)
was measured on the dorsum of the foot
immediately before percutaneous angio-
plasty, after the 1st month, and every 6
months thereafter. This parameter was
thought to monitor the efﬁcacy of the re-
vascularization procedure. If the TcPO2
value did not increase to 30 mmHg, the
threshold value thought to be necessary
for spontaneous wound healing, this pro-
cedurewouldberepeatedifpossible(13).
Revascularization procedure. Percuta-
neous angioplasty was performed in the
presence of signiﬁcant arterial stenosis
(50%oflumina)and/orobstruction.All
arteries were consistent with use of a per-
cutaneousangioplastyprocedureinterms
of respective site and length of the steno-
sis/obstruction. In some instances, these
were longer than 10 cm, multiple, se-
quential,orcalciﬁed.Allprocedureswere
performed under local anesthesia and a
bolus of 5,000 IU of sodium heparin was
immediately injected in the artery. A 6-Fr
vascular introducer was positioned to
perform a preliminary angiographic
study. An angiographic or percutaneous
transluminarcoronaryangioplasty0.014-
to 0.035-inch guidewire was inserted to
pass through the arterial obstruction fol-
lowedbya3.0-to5.0-Frballooncatheter.
This allowed dilatation of 2- to 8-mm di-
ameter arteries. In selected patients, self-
expandable stents were inserted in 5- to
8-mm diameter vessels. Stents were not
placed below the popliteal arteries as the
risk of thrombosis was very high in such
low-ﬂow vessels. In selected patients, a
subintimal approach was used. In brief,
subintimal angioplasty, also known as
percutaneousintentionalextraluminalre-
canalization, is a technique of revascular-
ization that creates a new lumen between
the intimal and medial layers (7). Patients
were treated with aspirin (100 mg/day)
and ticlopidine (500 mg/day) before the
revascularization procedure and treat-
ment was continued for 6 months there-
after. Long-term aspirin (100 mg)
prophylaxis was recommended.
Side effects included retroperitoneal
hematomas that occurred in 2.8% of pa-
tientsanddidresolvespontaneously.One
patient had a hemorrhage from the injec-
tionsitethatrequiredfasttreatmentinthe
operating theater. The occurrence of
thrombi was managed by catheter aspira-
tion and/or urokinase infusion. In only
three patients was it responsible for
a technical failure of the procedure.
Aggressive surgical debridement. The
surgical debridement was aimed to drain
abscesses, open ﬁstulas, and remove ne-
crotic and all clinically infected tissues
(14).Minoramputations,i.e.,amputation
oftoesand/ormetatarsalheads,werecon-
sidered as a part of the extensive debride-
ment. Some patients had initial treatment
before percutaneous angioplasty. This
wasperformedimmediatelyafterhospital
admission to limit the progression of in-
fection. These patients then underwent
additional more extensive debridement
after percutaneous angioplasty when a
signiﬁcantincreaseintheTcPO2valuewas
recorded at the ulcer site (12).
Infection treatment. Broad-spectrum
intravenous antibiotic therapy was given
immediately with a standard protocol
ofimipenemplusciproﬂoxacin.Aroutine
culture of the ulcer was done before anti-
biotic therapy was initiated. If necessary,
antibiotic treatment would be changed
depending on sensitivities of the organ-
isms identiﬁed. For osteomyelitis, diag-
nosed according to Infectious Diseases
SocietyofAmericaguidelines(14),thein-
fected bone was surgically removed.
Outcomes
The primary outcome measures were
healing, nonhealing, major amputation,
and mortality. The ﬁrst outcome reached
in one of these four categories was the
only outcome considered. The time re-
quired to reach these outcomes was also
recorded. Wound healing was deﬁned as
a continuous viable, epithelial covering
over all previously seen open wounds.
Major amputation was considered to be
any amputation above the ankle, and mi-
nor amputation was any amputation be-
low the ankle. Nonhealing was deﬁned as
unhealed ulceration after at least 1 year of
follow-up but no need for major amputa-
tion.Thesepatientshadapreservedfunc-
tional limb for ambulation and had no
signs of increasing infection.
Secondary outcomes were technical
failureoftherevascularizationprocedure,
measured as absence of revascularization
of any of the three leg vessels and absence
of direct arterial ﬂow to the foot. This was
considered as an immediate outcome. A
TcPO2 value 30 mmHg 1 month after
percutaneous angioplasty was considered
as an intermediate outcome.
Statistical analysis
Statistical analysis was performed using
SAS (release 6.12; SAS Institute, Cary,
NC) for personal computers. Data are ex-
pressed as means  SEM. Comparisons
between group characteristics were made
witha
2test(frequencydata)orANOVA
(continuous data). The time to event was
evaluated by means of a Kaplan-Meier
procedure.
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ses were performed for all potential pre-
dictor variables with the outcome of
interest, with values presented as univari-
able hazard ratios (HRs) along with the
respective 95% CI. All potential predic-
tors were entered simultaneously in a
multivariable regression and a set of vari-
ables that best predict outcome was iden-
tiﬁed. P  0.05 was considered
statistically signiﬁcant.
RESULTS— A total of 534 diabetic pa-
tients with CLI and lesions in class C (isch-
emia)andclassD(ischemiainfection)and
grade 2–3 (deep–very deep) of the TWC
were seen during the 5-year recruitment
period. Of these, 24 were lost after the
ﬁrst observation. The other 510 were in-
cluded in our study (mean follow-up
20  13 months [range 1–66 months]).
The clinical characteristics of the pa-
tients considered as a whole and divided
byoutcomesarereportedinTable1.Most
of the patients were aged 65 years
(75%), were male (63.5%), and had type
2 diabetes (93.3%) with a disease dura-
tion of 	20 years. The majority of the
patients had hypertension that was con-
trolled pharmacologically (91%); only a
small percentage of patients had end-
stage renal disease and were undergoing
hemodialysis (12.8%). A history of coro-
nary artery disease or cerebral ischemic
attack was present in 41.8 and 23.2% of
patients, respectively, and 21.4% were
smokers. Mean  SEM A1C was 7.2 
0.1%, and LDL cholesterol was 96.5  2
mg/100 ml. Of the ulcers, 46.3% had an
area 5c m
2, infection was present in
78.5%,and66.7%oftheulcerswereisch-
emic, infected including extension to the
bone (TWC D3). Baseline TcPO2 values
wereintherangeofsevereischemia(30
mmHg) in 81% of the patients. Percuta-
neous angioplasty was performed in
89.4% of patients.
Surgical debridement was performed
immediately at the ﬁrst observation, and
repeated, as necessary, throughout the
follow-up. All of the patients received in-
Table 1—Patients’ baseline characteristics according to their outcome
Total Healing Amputation Death Nonhealing
P value
(² ANOVA)
n (%) 510 310 (60.8) 80 (15.7) 83 (16.25) 37 (7.25)
Sex (% male) 63.5 63.2 67.5 62.65 59.5 0.83
Age (years) 70.4  0.8 69  1.6 70.3  17 5  1*† 69  1.6‡ 0.0001
Type 2 diabetes (%) 93.3 94.8 90.4 90.7 94.7 0.13
Diabetes duration (years) 20  1.4 20.1  0.7 19.4  1.4 19.3  1.3 21  2 0.07
Blood pressure therapy yes (%) 91 89.8 88.5 97.5 91.9 0.37
Diastolic blood pressure (mmHg) 135  0.9 136.7  0.8 131.4  1.6* 133.7  1.5 139.5  2.4† 0.0057
Systolic blood pressure (mmHg) 79  0.8 80.4  0.5 77.8  1 76.5  1* 80  1.5 0.0012
Dialysis yes (%) 12.8 8.09 23.75 19.28 13.51 0.0008
Ischemic heart disease yes (%) 41.8 38.16 49.37 40.24 59.46 0.041
Carotid stenosis yes (%) 23.2 19.9 31.25 26.51 25 0.16
Current smoker no (%) 78.6 78.2 74.7 81.7 78.6 0.61
Blood glucose (mg/dl) 140  5 143  3 142  7 127  6 136  10 0.17
A1C (%) 7.2  0.1 6.8  0.2 7.1  0.2 7.7  0.11* 7.4  0.3 0.0034
Total cholesterol (mg/dl) 159  3 163.5  2.4 154  5 155  4.7 146.6  7 0.053
HDL (mg/dl) 38  0.8 40  0.9 35.5  1.7 35.2  1.7* 37.3  2.5 0.002
Triglycerides (mg/dl) 137  3 138  4 138  7 138  7 131  10 0.90
LDL (mg/dl) 96.5  29 9  29 3  49 4  48 6  6 0.17
Ulcer dimension 5 cm (%) 46.3 39.9 66.7 45 55.9 0.0003
Infection yes (%) 78.5 76.3 83 78.8 84.8 0.74
TWC D3 (%) 66.7 62.7 76.6 72.1 64.5 0.10
Basal TcPo2 16.1  0.8 16.7  0.9† 10.3  1.7 17.9  1.7† 18.5  2.5† 0.0055
Basal TcPco2 54.8  1.4 53.2  1.5† 63.9  3.1 52  3† 56.4  4.4 0.0145
Emergency yes (%) 41.8 35.8 58.7 45.8 45.9 0.02
Minor amputation 260 (54) 145 (50) 31 (40) 30 (37) 18 (49) 0.12
Peripheral angioplasty yes 456 (89.4) 284 (91.6) 67 (83.7) 68 (81.9) 37 (100) 0.0009
1-month TcPo2 44.6  1.1 46.8  1.4 40  3.1 39  2.6* 41.8  3.2 0.0124
1-month TcPco2 40.7  0.7 39.3  0.8 44.3  2.1 44.6  1.7* 41.5  2.1 0.0127
TcPo2 27.6  1.4 30.2  1.5 25.6  4.1 18.4  3.5* 22.8  4 0.0096
TcPco2 13.9  1.7 15  1.9 16.8  5.3 4.2  4.4 15.8  5.3 0.14
Steno-obstructions (n) 2.6  0.06 2.6  0.07 2.8  0.14 2.4  0.1 2.8  0.14 0.29
Vessels treated (n) 1.8  0.041 1.8  0.05 1.7  0.1 1.8  0.1 1.9  0.1 0.69
Stent (one) (%) 25.2 25 26 20 24 0.29
Subintimal yes (%) 23 22.8 22.2 18 25.7 0.69
Percutaneous angioplasty technical
failure (%) 10.9 5.6 28.6* 16.1 11.1 0.0001
Data are n (%) or means  SEM or %. The variables related to PA patients only are shown in italic. *P  0.05 vs. healing. †P  0.05 vs. amputation. ‡P 
0.05 vs. death.
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weeks followed by oral antibiotic therapy
driven by results of cultures, repeated se-
rially, until the clinical signs of the infec-
tion disappeared.
The patients had the following out-
comes: 310 (60.8%) had healed wounds,
80 (15.7%) received a major amputation,
and 83 (16.25%) died after 9.4  0.5,
4.9  0.9, and 9  0.9 months, respec-
tively, and 37 (7.25%) had nonhealing
wounds after 23.2  1.4 months of ob-
servation (log-rank P  0.001).
In comparison with the other groups,
patients with healed wounds had smaller
ulcers and less coronary artery disease.
These patients had lower rates of dialysis
treatment and required less emergency
room care. The majority of the healed
wounds (51%) healed in 6 months. Ul-
cer area 5c m
2, infection, TWC D3, and
the presence of ischemic heart disease re-
duced signiﬁcantly the chance of healing
(HR 0.43 [95% CI 0.21–0.58[, P 
0.0001; 0.36 [0.22–0.58], P  0.0005;
0.44 [0.11–0.87], P  0.0054; 0.52
[0.12–0.94], P  0.0004, respectively) at
the monovariate analysis.
Patientswithamputationsunderwent
dialysis more frequently, and approxi-
mately half had ischemic heart disease.
They had lower basal TcPO2 and higher
transcutaneous carbon dioxide tension
(TcPCO2). They had signiﬁcantly lower
systolic blood pressure. More frequently,
they were recruited from the emergency
department. Ulcer area 5c m
2, infec-
tion, TWC D3, number of minor ampu-
tations, ischemic heart disease, dialysis,
and age were risk factors for major ampu-
tation (HR 2.3 [95% CI 1.2–5.6], P 
0.003; 1.7 [1.1–2.5], P  0.019; 1.6
[1.1–2.2],P0.018;2.04[1.2–3.3],P
0.003; 1.5 [1.01–2.4], P  0.05; 2.06
[1.2–3.6], P  0.004; and 1.02 [1.01–
1.05], P  0.02, respectively) in the
monovariate analysis.
Patientswhodiedwereolderthanthe
patients in other groups and had higher
A1C and lower HDL cholesterol and dia-
stolic blood pressure. They were treated
with percutaneous angioplasty at a lower
percentage. Age was identiﬁed as a mor-
tality risk factor (HR 1.022 [95% CI
1.001–1.052], P  0.03).
Patients with nonhealing wounds
had a higher percentage of ischemic
heart disease; 	56% had an ulcer 5
cm
2. Basal TcPO2 was signiﬁcantly
higher than in the group with amputa-
tions. Percutaneous angioplasty was
done in all patients.
The multivariate analysis includes all
of the signiﬁcant variables found in the
monovariate analysis. Predicting vari-
ables at multivariate analysis were the fol-
lowing: for healing, ulcer dimension,
infection, and ischemic heart disease (HR
0.41 [95% CI 0.18–0.58], P  0.0001;
0.37 [0.11–0.57], P  0.0001; and 0.54
[0.15–0.82], P  0.0001, respectively);
and for major amputation, ulcer dimen-
sion, number of minor amputations, and
age (7.7 [1.2–12.07], P  0.0002; 3.09
[1.7–5.7],P0.0001;and1.3[1.2–1.7],
P  0.03, respectively). None of these
variableswerestatisticallyassociatedwith
mortality or nonhealing outcomes.
To better highlight the inﬂuence of
percutaneous angioplasty on outcomes, a
further analysis was performed, dividing
thewholepatientgroupaccordingtoper-
cutaneous angioplasty treatment: 456 pa-
tients were treated with percutaneous
angioplasty (PA), 54 patients were not
treated with percutaneous angioplasty
(PA). The two groups had signiﬁcantly
different outcomes for PA and PA, re-
spectively: healing, n  284 (62.3%) and
n  26 (48.1%); major amputation, n 
67 (14.7%) and n  13 (24.1%); de-
ceased, n  68 (14.9) and n  15
(27.8%); and nonhealing, n  37 (8.1%)
andn0(0%)(
20.0009).Differences
intimetoeventwereobservedonlyinthe
time to amputation, which in the PA
group was signiﬁcantly shorter than that
in the PA group (1.2  1 vs. 5.2  1
months, P  0.01).
The two groups did not differ for any
of the variables listed in Table 1 (data not
shown). Additional variables related to
PA were described only in PA patients
and are reported in Table 1.
The number of arterial stenosis that
were hemodynamically relevant (50%)
and/or with obstruction detected was
2.6  0.06, and the number of vessels
treated by percutaneous angioplasty
was1.80.04/patient.Thetreatedarter-
ies were localized below the knee (35%)
and above the knee (34%); the remaining
were treated at both levels. Stents were
used in 25.2% of patients, whereas subin-
timal recanalization was necessary only in
23% of patients. Technical failure was sig-
niﬁcantly lower in the patients with healed
wounds than in the patients with amputa-
tions, which indeed had the highest failure
rate (P  0.0001). Major amputation was
signiﬁcantly associated with the technical
failureoftheprocedure(
20.0001),and
technicalfailurewassigniﬁcantlyassociated
with a precocious amputation after percu-
taneous angioplasty (1.5  1.5 vs. 6.1  1
months, P  0.02) in comparison to the
time of amputation observed in the techni-
cally successful percutaneous angioplasty
procedures. TcPO2 and TcPCO2 values were
used to monitor short-term (1 month) efﬁ-
cacy of the revascularization procedure (in-
termediate outcome).
Patients with healed wounds had a
1-month TcPO2 value that was increased
signiﬁcantly compared with the baseline
(46.8  1.4 vs. 15.7  0.8 mmHg, P 
0.001), and 1 month after percutaneous
angioplastytheTcPCO2valuesigniﬁcantly
decreased compared with the baseline
(39.3  0.8 vs. 54.7  1.4 mmHg, P 
0.0001).Therevascularizationprocedure
was repeated in 43 patients (9.4%) and in
37 (86%) patients within the 1st month
after the initial percutaneous angioplasty.
Surgical bypass was performed in 12 pa-
tients (2.6% of the total) after failure of a
repeated percutaneous angioplasty.
In the multivariate analysis including
only PA patients (Table 2), in a model
containing age, ulcer dimension 5c m
2,
infection, TWC D3, basal blood glucose,
basalA1C,presenceofischemicheartdis-
ease, number of minor amputations, per-
cutaneous angioplasty technical failure,
basal TcPO2, TcPO2, the predicting vari-
ables for healing were ulcer dimension,
infection, the presence of ischemic heart
disease, and TcPO2. Predicting variables
for major amputation were ulcer dimen-
sion,basalA1C,age,percutaneousangio-
plasty technical failure, basal TcPO2, and
TcPO2. None of these variables were as-
sociated to mortality or nonhealing.
CONCLUSIONS — Lower limb am-
putation is a complication of diabetes
mainly due to the presence of PVD (3,9).
It is much rarer for PVD by itself to be
responsible for lower extremity amputa-
tion. In the majority of patients, a small
skin lesion, insigniﬁcant in appearance,
often due to trivial causes, becomes in-
fected and enlarges. All too commonly
gangrene follows (13).
There is increasing evidence that dis-
tal arterial revascularization offers the best
chance for limb salvage in diabetic patients
with CLI. Outcomes reported in the litera-
ture are not always comparable (9,15).
Studies detailing outcomes such as healing,
major amputation, and mortality are still
lacking.Therefore,theimpactofperipheral
revascularization on the natural history of
diabetic patients with CLI followed over a
long period is still obscure. Although TASC
(9) gives strict criteria about objective mea-
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TcPO2) to deﬁne patients affected by CLI,
the criteria fail to separate out patients with
ulceration or gangrene.
Several authors have attempted to
classify wounds (16,17). Armstrong et al.
(10) proposed wound classiﬁcation re-
lated to the presence of ischemia and/or
infection and to wound depth. The same
authors in a follow-up study described
the natural history of patients according
to the severity of the wounds. They re-
ported an amputation rate of 28% for pa-
tients with a superﬁcial ischemic ulcer
(TWC C1) over 6 months, and an ampu-
tation rate of 100% (including minor and
major) for patients with deep, infected,
ischemic lesions (TWC D3) (11). These
data suggested that the efﬁcacy of a limb
salvage protocol might be highly affected
by the clinical characteristics of the
wounds included in the study. Therefore,
althoughadistalrevascularizationmaybe
sufﬁcient alone to deal with ischemic
nonhealing superﬁcial ulcers, a much
more complex treatment protocol may be
needed for deep, infected ischemic
wounds and/or gangrene. No studies,
evenrecently,havelinkedtheefﬁcacyofa
limb salvage protocol to ulcer dimension.
Faglia et al. (18) in their recent report de-
scribed in detail the outcomes of a group
of diabetic patients with CLI but did not
describe the type and the extent of the
lesionsandthepresenceofinfection.Laz-
arisetal.(19)describedapopulationwith
only 33 diabetic subjects. In addition, in
this report there is no description of the
lesions. In the article by DeRubertis et al.
(15), only 31.4% had a generic tissue loss
and among the total 291 patients only
one-half were diabetic subjects. In addi-
tion,thelimbsalvagerateisreportedonly
at 1 year. The recent report of the Euro-
diale study focused attention on the char-
acteristics of foot ulceration (size, depth,
and infection); however, our data are not
comparable with those reported in the
Eurodiale study. In that study, only 40
(22%)ofthe181patientswithnonhealing
woundsoramputationsunderwentrevas-
cularization, and only 40 (42.5%) of 94
patients with ankle-brachial index 0.5
underwent revascularization (20).
In this study, our diabetic patients
with CLI were characterized by using the
TWC.Oftheulcers,80%hadaninfection
(TWC D]) and in 	70% the infected ul-
cers were deep to the bone (TWC D3).
This ﬁnding implies that our patients had
worse prognoses according to both TASC
and TWC, with the highest risk of lower
limb amputation.
Thisreportshowsthatitispossibleto
savethelimbin	70%ofthepatientsand
to obtain wound healing in  60% of
wounds in a relatively short time. The ap-
proach shows improved results in terms
of outcomes compared with those of the
TASC, which reported a 25% mortality
rate, 30% major amputation rate, and
only 45% surviving with the two intact
lower extremities at 1-year follow-up (9).
Inparticular,aggressiveearlysurgical
debridement appears to be crucial in the
management of these patients. This ex-
plains the relatively high number of mi-
nor amputations that have been done to
limit gangrene progression. It is notewor-
thy that the number of minor amputa-
tions is a risk factor for a major
amputationintheunivariateanalysis.De-
layed debridement allows infection to de-
stroysigniﬁcantportionsofthefoot.Even
successful revascularization failed with
deep infection because of the foot anat-
omy characterized by closed compart-
ments predisposed to progression (21).
Aggressive surgical management is criti-
cal when infection spreads from an ulcer
into these compartments. There is a rapid
progression of infection through empty
space. In this situation a large surgical ap-
proach to open the foot compartments is
required to avoid further spread of the
infection and worsening of the gangrene.
Antibiotictherapyisalsoimportantin
ourexperience;combinedantibioticther-
apy has efﬁcacy, including early clinical
improvement. In only a few patients was
it necessary to change the antibiotic ther-
apy due to antibiotic resistance.
Over the last few years percutaneous
angioplasty has earned increased respect
in the treatment of PVD in diabetic pa-
tients(6,22).Thisisourmethodofchoice
to treat peripheral ischemia.
In our experience, percutaneous an-
gioplasty has been tried in almost all pa-
tients (	90%). A small group of patients
was not treated with percutaneous angio-
plasty. The indication to skip percutane-
ous angioplasty was related to their
generalconditionsortotheextensionand
evolution of the foot lesion. In 15 pa-
tients, percutaneous angioplasty was not
performed because of the presence of se-
vere comorbidities (almost all of those pa-
tients died within 6–12 months); in 13
patients,theextensionofthefootlesionwas
incompatible with limb salvage, and they
were treated by primary major amputation.
In 26 patients, percutaneous angioplasty
wasnotperformedbecausethelesionswere
small and showed a relatively fast evolution
to spontaneous healing.
Percutaneous angioplasty was tried in
all of the other patients. Patients in whom
percutaneousangioplastyfailed,eitherasan
indextreatmentorrevision,alsohadanun-
successful surgical approach with open by-
pass. Percutaneous angioplasty has been
shown to be safe overall with a very low
complication rate. In addition, percutane-
ousangioplastyisstilltechnicallyfeasiblein
the presence of infected wounds of the
lower limb, whereas the open surgical ap-
proach may be contraindicated. It has been
effective with femoral, tibial, and peroneal
arteries, both with standard techniques and
with a subintimal approach (7,19).
From a technical point of view, per-
cutaneous angioplasty has been per-
formed in almost all stenoses and/or
obstructions independent of length, in
the presence of arterial calciﬁcations, and
also in the presence of multiple stenoses.
Technical success has been extremely
Table 2—Multivariate model with independent predictors of events for patients undergoing
percutaneous angioplasty
Healing P value Amputation P value
Age (years) 1.11 (1.015–1.258) 0.0237
Ulcer dimension (5t o
5 cm) 0.358 (0.223–0.573) 0.0001 5.2 (1.2–12.5) 0.0051
Infection (yes–no) 0.431 (0.223–0.851) 0.0157
A1C (basal) 4.01 (1.58–13.05) 0.0025
Ischemic heart disease
(yes–no) 0.382 (0.242–0.591) 0.0001
Percutaneous angioplasty
technical failure (yes–no) 0.05 (0.002–0.537) 0.0117
Basal TcPo2 (mmHg) 0.891 (0.804–0.967) 0.0044
DTcPo2 (mmHg) 1.016 (1.004–1.027) 0.0051 0.953 (0.91–0.99) 0.02
Data are HR (95% CI). No predictors for death and nonhealing.
Uccioli and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 5, MAY 2010 981high and supports the aggressive ap-
proach of peripheral revascularization
with the aim to revascularize as much as
possible wherever and whenever a suit-
able lesion is found. Multivariate analysis
of the technical success of percutaneous
angioplasty does show a signiﬁcant re-
duction for the risk of major amputation;
1-month TcPO2 is also signiﬁcantly as-
sociated with healing and with a reduced
risk of major amputation.
These patients often have coexistent
coronary artery disease and percutaneous
angioplasty offers the potential advantage
that, where performed, the veins that could
be necessary for cardiac bypass are spared.
However, failed percutaneous angioplasty
also does not exclude a surgical approach
withopenbypass,which,inourexperience,
offered no additional clinical beneﬁt after
failed percutaneous angioplasty bypass.
Another important topic concerns
how the dimensions of the ulcer and the
presence of infection inﬂuence the out-
comes of these patients with CLI. Ulcer
size 5c m
2 alone is a large risk factor for
amputation. Our data support the logic
that larger-sized ulcers have a larger am-
putation rate. Obviously no lesion caused
by PVD starts this large, justifying the
more aggressive approach of our protocol
to smaller lesions, which our study has
shown to have improved outcomes.
Multivariate analysis of our study
echoesﬁndingsthatbasalA1Clevelsarea
risk factor for amputation, and in similar
studies hyperglycemia in perioperative
patients has been identiﬁed as a separate
risk factor for morbidity and mortality
(23). Our data suggest that the treatment
of the ischemic ulcers with aggressive re-
vascularization reduces the risk of major
amputation. This is also further sup-
ported by the Eurodiale study (20).
Analysis of the data allows outcome com-
parison among centers. Centers with the
best outcomes used vascular imaging, re-
vascularization, surgery, and other imag-
ing modalities more aggressively (20).
In summary, our comprehensive ap-
proach allows the salvage of limbs that
otherwise may be amputated. Crucial le-
sion procedures early and aggressive
debridement, revascularization by percu-
taneous angioplasty, multiagent intrave-
nous antibiotic therapy, and controlled
follow-up. It is our conviction that this
approach can save many legs that previ-
ously would have been amputated.
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